Summary
L-644,122 is a chemically stable vasodilator prostaglandin analogue. It is a selective renal vasodilator in dogs. The object of the present study was to determine whether it increases effective renal plasma flow (ERPF) in man. L-644,122 was administered intravenously to 4 healthy volunteers and by mouth to 4 mild hypertensives. It did not increase ERPF. Instead it acted as a non-specific vasodilator, lowering diastolic blood pressure and increasing heart rate. An unexpected increase in glomerular filtration rate (19% greater than placebo) after low dose intravenous L-644,122 merits further study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bergstrom S, Duner H, v. Euler US, Pernow B, Sjovall J (1959) Observations on the effects of infusion of prostaglandin E in man. Acta Physiol Scand 45: 145–151
Bicking JB, Bock MG, Cragoe EJ, DiPardo RM, Gould NP, Holtz WJ, Lee T-J, Robb CM, Smith RL, Springer JP, Blaine EH (1983) Prostaglandin isosteres. 2. Chain-modified thiazolidinone prostaglandin analogues as renal vasodilators. J Med Chem 26: 342–348
Blaine EH (1983) Reversal of indomethacin-induced decreases in renal function by an isosterically modified protaglandin analog. Prostaglandins 26: 805–815
Blaine EH, Russo HF, Schorn TW, Snyder C (1982) An orally active prostaglandin analog with renal vasodilatory activity in the dog. J Pharmac Exp Ther 222: 152–158
Earle DP, Berliner RW (1946) A simplified clinical procedure for measurement of glomerular filtration rate and renal plasma flow. Proc. Soc Exp Biol Med 62: 262–264
Henry JA, Thrower PA, Smith PR, O'Grady J (1981) Effects of prostacyclin on renal function in man. In: Lewis PJ, O'Grady J (eds) Clinical pharmacology of prostacyclin. Raven Press, New York, pp 83–88.
Hornych A, Safar M, Papanicolaou N, Meyer P, Milliez P (1973) Renal and cardiovascular effect of prostaglandin A2 in hypertensive patients. Eur J Clin Invest 3: 391–398
Karim SMM, Somers K, Hillier K (1971) Cardiovascular and other effects of prostaglandins E2 and F2α in man. Cardiovasc Res 5: 255–259
Kaufman RG, Freeman RK, Mishell DR (1971) Abortifacient activity of intravenously administered prostaglandins. Contraception 3: 121–132
Lee JB, McGiff JC, Kannegiesser H, Aykert YY, Mudd JG, Frawley TF (1971) Prostaglandin A1: Antihypertensive and renal effects. Ann Intern Med 74: 703–710
Levinsky NG, Alexander EA, Veukatachalam MA (1981) Acute renal failure. In: BM Brenner, FC Rector (eds). The kidney, volume 1 WB Saunders, Philadelpha London Toronto, pp 1181–1236
Orchard MA, Ritter JM, Shepherd GL, Lewis PJ (1983) Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2). Br J Clin Pharmacol 15: 509–511
Pickles H, O'Grady J (1982) Side-effects occurring during administration of epoprostenol (prostacyclin, PGI2) in man. Br J Clin Pharmacol 14: 177–185
Seymour AA, Blaine EH (1983) Renal vasodilation by a prostaglandin analog during dopaminergic and alpha-adrenergic blockade. Prostaglandins Leukotrienes Med 10: 349–360
Smith HW (1956) Principles of renal physiology. Oxford University Press, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ritter, J.M., Ludgin, J.R., Scharschmidt, L.A. et al. Effects of a stable prostaglandin analogue, L-644,122, in healthy and hypertensive men. Eur J Clin Pharmacol 28, 685–688 (1985). https://doi.org/10.1007/BF00607916
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607916